Re-evaluating post-polypectomy surveillance: The role of non-invasive modalities in colorectal cancer prevention
Best Practice & Research Clinical Gastroenterology · 2026
DOI: 10.1016/j.bpg.2026.102092 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026. Verfasst von Ethna McFerran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Queen's University Belfast, UK. Electronic address: e.mcferran@qub.ac.uk. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Polyps, Early Detection of Cancer, Adenoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute, Health Research Board, Ipsen Biopharmaceuticals.
Abstract (Originalsprache)
Post-polypectomy surveillance is a cornerstone of colorectal cancer (CRC) prevention, yet current reliance on colonoscopy poses challenges related to capacity, patient burden, and adherence. Amid growing interest in non-invasive strategies, this review evaluates the diagnostic performance, clinical applicability, and limitations of emerging alternatives, including faecal immunochemical testing (FIT), multitarget stool DNA (mt-sDNA), CT colonography (CTC), circulating tumour DNA (ctDNA), and colon capsule endoscopy (CCE), in the context of post-polypectomy surveillance. While FIT remains widely endorsed for low-risk populations, its limited sensitivity for flat adenomas and serrated lesions constrains its utility. mt-sDNA and CTC offer incremental improvements in detection but face cost-effectiveness, false-positive, and guideline limitations in surveillance. ctDNA holds promise for recurrence monitoring in high-risk CRC but remains investigational for adenoma surveillance. Evidence for CCE as a triage tool is emerging, though concerns persist regarding incomplete examinations, cost, and residual risk. Importantly, substantial heterogeneity in surveillance guidelines and suboptimal real-world adherence complicate evaluation and implementation of these modalities. Integration of molecular biomarkers and risk-adaptive strategies may support more personalised follow-up. However, robust comparative effectiveness studies that account for system-level and behavioural factors are essential to guide appropriate adoption. Non-invasive tools remain complementary, not yet replacements, for colonoscopy in post-polypectomy care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Queen's University Belfast, UK. Electronic address: e.mcferran@qub.ac.uk.
- South Eastern Health & Social Care Trust, UK.
- Queen's University Belfast, UK; Belfast Health and Social Care Trust, UK.
- Queen's University Belfast, UK.
- University of Glasgow, UK.
Förderung
- National Cancer Institute
- Health Research Board
- Ipsen Biopharmaceuticals
- Gilead Sciences
- Marie Curie
- Health Data Research UK
- Bowel Cancer UK
Zitieren
APA
McFerran, E., McKay, D., Loughrey, M. B., Lawler, M., & McSorley, S. T. (2026). Re-evaluating post-polypectomy surveillance: The role of non-invasive modalities in colorectal cancer prevention. Best Practice & Research Clinical Gastroenterology. https://doi.org/10.1016/j.bpg.2026.102092
Vancouver
McFerran E, McKay D, Loughrey MB, Lawler M, McSorley ST. Re-evaluating post-polypectomy surveillance: The role of non-invasive modalities in colorectal cancer prevention. Best Practice & Research Clinical Gastroenterology. 2026. doi:10.1016/j.bpg.2026.102092
BibTeX
@article{McFerran2026,
author = {McFerran, Ethna and McKay, Damian and Loughrey, Maurice B and Lawler, Mark and McSorley, Stephen T},
title = {Re-evaluating post-polypectomy surveillance: The role of non-invasive modalities in colorectal cancer prevention},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2026},
doi = {10.1016/j.bpg.2026.102092}
}
EUVIMED